Castle Biosciences has completed its purchase of Cernostics for $30 million. The company will pay up to $50 million more if Cernostics fulfills particular milestones in 2022.
The acquisition expands Castle's offerings to include Cernostics' TissueCypher Barrett's Esophagus Assay, a test that predicts future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, it said.
